Exclusive Summary

• Differentiated sustained-release formulation: Compared to conventional tablets, SR capsules offer smoother drug release, reducing dosing frequency and gastrointestinal irritation, thereby significantly enhancing patient compliance for long-term chronic pain management.
• Superior cardiovascular safety profile: As a classic NSAID recommended by international clinical guidelines, Naproxen exhibits the lowest cardiovascular risk among peers, making it the preferred choice for pain patients with high risks of heart attack or stroke.
• Massive and resilient market demand: With over 528 million osteoarthritis patients globally, driven by the rapidly aging population, long-acting anti-inflammatory analgesics guarantee a stable, immense, and rigid market need.
• Highly lucrative distribution margins: Free from patent barriers and leveraging China's ultra-competitive API-to-finished dosage manufacturing cost advantages, this product secures exceptional profit margins and flexible pricing power for overseas distributors.
• Agile regulatory and registration support: Supported by ICH-compliant, high-quality CTD dossiers provided by the manufacturer, distributors can achieve rapid local market authorization and commercial monetization without regulatory bottlenecks.